U.S. markets open in 9 hours
  • S&P Futures

    3,933.75
    +11.25 (+0.29%)
     
  • Dow Futures

    32,029.00
    +113.00 (+0.35%)
     
  • Nasdaq Futures

    13,347.00
    +45.00 (+0.34%)
     
  • Russell 2000 Futures

    2,301.40
    +16.30 (+0.71%)
     
  • Crude Oil

    63.27
    +0.05 (+0.08%)
     
  • Gold

    1,795.80
    -2.10 (-0.12%)
     
  • Silver

    28.10
    +0.24 (+0.87%)
     
  • EUR/USD

    1.2186
    +0.0018 (+0.15%)
     
  • 10-Yr Bond

    1.3890
    -1.3620 (-100.00%)
     
  • Vix

    21.34
    -23.11 (-100.00%)
     
  • GBP/USD

    1.4168
    +0.0027 (+0.19%)
     
  • USD/JPY

    105.8660
    -0.0160 (-0.02%)
     
  • BTC-USD

    49,859.53
    -1,027.48 (-2.02%)
     
  • CMC Crypto 200

    995.56
    +0.88 (+0.09%)
     
  • FTSE 100

    6,658.97
    +33.03 (+0.50%)
     
  • Nikkei 225

    30,107.69
    +435.99 (+1.47%)
     

Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, June 9, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa, Chief Executive Officer of Relmada, will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference, being held June 9-11, 2020.

Relmada Therapeutics Corporate Logo
Relmada Therapeutics Corporate Logo

Fireside Chat Details:


Date:


Thursday, June 11, 2020

Time:


3:00 PM EDT

Webcast:


A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: www.relmada.com. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel medicines to address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. Relmada's lead program, REL-1017 (dextromethadone) is an N-methyl-D-aspartate (NMDA) receptor antagonist in development for the treatment of depression. NMDA receptor antagonists may have utility in the treatment of a range of psychiatric and neurological disorders associated with a variety of cognitive, neurological and behavioral symptoms.

Investor Contact:

Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com

For Media Inquiries:
FischTank PR
relmada@fischtankpr.com

Cision
Cision

View original content to download multimedia:http://www.prnewswire.com/news-releases/relmada-therapeutics-to-present-at-the-goldman-sachs-41st-annual-global-healthcare-conference-301072754.html

SOURCE Relmada Therapeutics, Inc.